NCT05014399Recruiting
Cognitive Impairment in Colorectal Cancer Patients Receiving Cytotoxic Chemotherapy
Source: ClinicalTrials.gov · Last updated 14 Aug 2026
Brief summary (registry, in English)
The purpose of this research study is to see how the brain changes in patients receiving chemotherapy (cytotoxic drug) treatment for colon or rectal cancer at Parkview Cancer Institute. This information will be used to identify helpful tests to diagnose individuals at risk for developing difficulties with thinking and memory due to their cancer treatments.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 60 (estimated)
- First submitted
- 3 Aug 2021
- Start date
- 20 Sept 2021
- Primary completion date
- Oct 2028
- Lead sponsor
- Joseph McCollom
- Diseases
- Colorectal cancer
- NCT number
- NCT05014399
What you commit to
- Study type: Observational
- Planned participants: 60
- From 20 Sept 2021 to the primary completion date, Oct 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior administration of anti-cancer chemotherapy, radiotherapy, immunotherapy, or investigational agents
Other illness
- Patients who have been diagnosed with any neuro-cognitive disorder including traumatic brain injuries, Alzheimer's disease, Parkinson's disease, Huntington's disease, and Creutzfeldt-Jakob disease.
Other
- Patients having mental incompetence as assessed by study PI, which would hinder completion of the surveys
- Pregnant or breastfeeding
- Any known brain metastases
- Non-English speaking patients
- Patients deemed inappropriate to participate in this study by the study PI or coordinator will be excluded.
Who the study is looking for
- Signed written informed consent must be obtained and documented according to International Conference on Harmonisation (ICH)- Good Clinical Practice (GCP), the local regulatory requirements, and permission to use private health information in accordance with the Health Insurance Portability and Accountability Act (HIPAA) prior to study-specific screening procedures. Must be able to provide study-specific informed consent prior to study entry.
- A histologically-confirmed colorectal tumor
- Patients who will be treated with cytotoxic chemotherapies including Capecitabine, Oxaliplatin, 5 fluorouracil, and Irinotecan are eligible.
- Patients must not have received cytotoxic chemotherapy previous to enrollment.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Parkview Cancer Institute Coordinator of this site? Confirm its status | Fort Wayne | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.